Scientists Achieve Year-Long Room-Temperature Vaccine Stability

Scientists have successfully maintained the stability of several key vaccines at ambient room temperature for an entire year, a breakthrough that could dramatically alter the logistics of global immunization programs. The study, conducted by researchers at the International Vaccine Institute and published in *Nature Medicine*, tested a range of vaccines—including those for measles, polio, and influenza—using a novel lyophilized formulation combined with a proprietary stabilizing excipient. Over 12 months, the vaccines retained over 95 % of their potency in controlled laboratory conditions that mimic typical storage environments in low‑resource settings.

The implications of this development are far-reaching. Current vaccine distribution relies heavily on cold‑chain infrastructure, which is costly, fragile, and often inaccessible in remote or under‑developed regions. By eliminating the need for refrigeration, health agencies could reduce shipping costs, lower waste from spoilage, and accelerate rollout during outbreaks. The research team is now collaborating with the World Health Organization and several national ministries of health to pilot field trials in sub‑Saharan Africa and Southeast Asia, aiming to validate the shelf‑life claims under real‑world conditions and to assess the feasibility of large‑scale production.

If the findings hold in broader deployments, the ability to store vaccines at room temperature for extended periods could streamline supply chains, improve coverage rates, and enhance pandemic preparedness worldwide. The next phase will involve scaling manufacturing, securing regulatory approvals, and integrating the new formulations into existing immunization schedules, potentially marking a pivotal shift toward more resilient and equitable vaccine delivery systems.